CINRG pilot trial of coenzyme Q10 in Steroid-Treated duchenne muscular dystrophy

Children's National Medical Center, George Washington University, Washington, DC, USA.
Muscle & Nerve (Impact Factor: 2.28). 08/2011; 44(2):174-8. DOI: 10.1002/mus.22047
Source: PubMed


Corticosteroid treatment slows disease progression and is the standard of care for Duchenne muscular dystrophy (DMD). Coenzyme Q10 (CoQ10) is a potent antioxidant that may improve function in dystrophin-deficient muscle.
We performed an open-label, "add-on" pilot study of CoQ10 in thirteen 5-10-year-old DMD patients on steroids. The primary outcome measure was the total quantitative muscle testing (QMT) score.
Twelve of 16 children (mean age 8.03 ± 1.64 years) completed the trial. Target serum levels of CoQ10 (≥2.5 μg/ml) were shown to be subject- and administration-dependent. Nine of 12 subjects showed an increase in total QMT score. Overall, CoQ10 treatment resulted in an 8.5% increase in muscle strength (P = 0.03).
Addition of CoQ10 to prednisone therapy in DMD patients resulted in an increase in muscle strength. These results warrant a larger, controlled trial of CoQ10 in DMD.

Download full-text


Available from: Ksenija Gorni,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Genetics continue to dominate the neuromuscular literature. The past 3 months have seen major breakthroughs in the genetics of amyotrophic lateral sclerosis and of Charcot-Marie-Tooth disease, perhaps paving the way for better treatments in the near future. On a hopeful note, there are several articles on treatments that may prove to be beneficial, covering such diverse disorders as chemotherapy-induced peripheral neuropathy, Duchenne muscular dystrophy, dermatomyositis, and myasthenia gravis. Useful descriptive articles appear on myofibrillar myopathies, hyperCKemia, and on myasthenia gravis associated with anti-muscle-specific tyrosine kinase antibodies, all of which provide helpful guidelines for clinicians. Finally, for those involved in electromyography, an article and an editorial address the recurring question of the risk of performing a needle examination of muscles (particularly paraspinal muscles) of patients who are taking anticoagulants or antiplatelet agents.
    Journal of clinical neuromuscular disease 12/2011; 13(2):98-103. DOI:10.1097/CND.0b013e31823e8247
  • [Show abstract] [Hide abstract]
    ABSTRACT: DMD is a devastatingly progressive muscle wasting disorder of childhood that significantly shortens life expectancy. Despite efforts to develop an effective therapy that dates back over a century, clinical interventions are still restricted to management of symptoms rather than a cure. The rationale to develop effective therapies changed in 1986 with the discovery of the dystrophin gene. Since then extensive research into both the molecular basis and pathophysiology of DMD has paved the way not only for development of strategies which aim to correct the primary defect, but also towards the identification of countless therapeutic targets with the potential to alleviate the downstream pathology. In addition to gene and cell-based therapies, which aim to deliver the missing gene and/or protein, an exciting spectrum of pharmacological approaches aimed at modulating therapeutic targets within DMD muscle cells through the use of small drugs are also being developed. This review presents promising pharmacological approaches aimed at targeting the primary defect, including suppression of nonsense mutations and functional compensation by upregulation of the dystrophin homologue, utrophin. Downstream of the primary membrane fragility, inflammation and fibrosis are reduced by blocking NF-κB, TGF-α and TGF-β, and free radical damage has been targeted using antioxidants and dietary/nutritional supplements. There are new hopes that ACE and PDE5 inhibitors can protect against skeletal as well as cardiac pathology, and modulating Ca2+ influx, NO, BMP, protein degradation and the mitochondrial permeability pore hold further promise in tackling the complex pathogenesis of this multifaceted disorder.
    Current Gene Therapy 05/2012; 12(3):206-44. DOI:10.2174/156652312800840595 · 2.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The recent development of therapeutic approaches for Duchenne muscular dystrophy (DMD) has highlighted the need to identify clinical outcome measures for planned efficacy studies. Although several studies have reported the value of functional scales, timed tests, and measures of endurance aimed at ambulant individuals, less has been done to identify reliable measures of function in individuals who have lost ambulation. The aim of this paper is to provide a critical review of the existing literature on functional measures assessing upper extremity function in DMD. Four observer-rated, performance-based measures and four self-reported scales have been previously used in DMD. Each scale provides useful information but none reflects all the different levels of functional ability in activities of daily living observed in individuals with DMD at different ages.
    Developmental Medicine & Child Neurology 06/2012; 54(10):879-885. DOI:10.1111/j.1469-8749.2012.04345.x · 3.51 Impact Factor
Show more